Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Role of cerium oxide in bioactive glasses during catalytic dissociation of hydrogen peroxide.

Benedetti F, Amidani L, Pelli Cresi JS, Boscherini F, Valeri S, D'Addato S, Nicolini V, Malavasi G, Luches P.

Phys Chem Chem Phys. 2018 Sep 19;20(36):23507-23514. doi: 10.1039/c8cp02271b.

PMID:
30183019
2.

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P.

Clin Cancer Res. 2018 May 1. doi: 10.1158/1078-0432.CCR-18-0455. [Epub ahead of print]

PMID:
29716920
3.

Correction to "Evidence of Catalase Mimetic Activity in Ce3+/Ce4+ Doped Bioactive Glasses".

Nicolini V, Gambuzzi E, Malavasi G, Menabue L, Menziani MC, Lusvardi G, Pedone A, Benedetti F, Luches P, D'Addato S, Valeri S.

J Phys Chem B. 2017 Jul 13;121(27):6773. doi: 10.1021/acs.jpcb.7b05993. Epub 2017 Jun 30. No abstract available.

PMID:
28664737
4.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P.

Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.

5.

SiO₂-CaO-P₂O₅ Bioactive Glasses: A Promising Curcuminoids Delivery System.

Nicolini V, Caselli M, Ferrari E, Menabue L, Lusvardi G, Saladini M, Malavasi G.

Materials (Basel). 2016 Apr 15;9(4). pii: E290. doi: 10.3390/ma9040290.

6.

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, Moessner E, Ast O, Bruenker P, Grau-Richards S, Schaller T, Seidl A, Gerdes C, Perro M, Nicolini V, Steinhoff N, Dudal S, Neumann S, von Hirschheydt T, Jaeger C, Saro J, Karanikas V, Klein C, Umaña P.

Clin Cancer Res. 2016 Jul 1;22(13):3286-97. doi: 10.1158/1078-0432.CCR-15-1696. Epub 2016 Feb 9.

7.

Evidence of catalase mimetic activity in Ce(3+)/Ce(4+) doped bioactive glasses.

Nicolini V, Gambuzzi E, Malavasi G, Menabue L, Menziani MC, Lusvardi G, Pedone A, Benedetti F, Luches P, D'Addato S, Valeri S.

J Phys Chem B. 2015 Mar 12;119(10):4009-19. doi: 10.1021/jp511737b. Epub 2015 Mar 3. Erratum in: J Phys Chem B. 2017 Jul 13;121(27):6773.

PMID:
25710332
8.

Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.

Lopergolo A, Nicolini V, Favini E, Dal Bo L, Tortoreto M, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani E, Borrello MG, Zaffaroni N, Cassinelli G, Lanzi C.

J Clin Endocrinol Metab. 2014 Feb;99(2):498-509. doi: 10.1210/jc.2013-2574. Epub 2013 Nov 25.

PMID:
24276455
9.

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.

Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.

10.

Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.

Nicolini V, Cassinelli G, Cuccuru G, Bongarzone I, Petrangolini G, Tortoreto M, Mondellini P, Casalini P, Favini E, Zaffaroni N, Zunino F, Lanzi C.

Biochem Pharmacol. 2011 Oct 1;82(7):778-88. doi: 10.1016/j.bcp.2011.06.037. Epub 2011 Jul 2.

PMID:
21741956
11.

Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.

Cassinelli G, Ronchetti D, Laccabue D, Mattioli M, Cuccuru G, Favini E, Nicolini V, Greco A, Neri A, Zunino F, Lanzi C.

Biochem Pharmacol. 2009 Nov 1;78(9):1139-47. doi: 10.1016/j.bcp.2009.06.023. Epub 2009 Jun 23.

PMID:
19555670
12.

Targeting RET for thyroid cancer therapy.

Lanzi C, Cassinelli G, Nicolini V, Zunino F.

Biochem Pharmacol. 2009 Feb 1;77(3):297-309. doi: 10.1016/j.bcp.2008.10.033. Epub 2008 Nov 6.

PMID:
19028457

Supplemental Content

Loading ...
Support Center